CXCL9 and CXCL10, by binding to their receptor CXCR, can attract and activate anti-tumor immune cells such as CD8+ T cells and natural killer (NK) cells, thereby enhancing their ability to eliminate tumor cells [108, 109]. This evidence concerns the gene CD8A and neoplasm.